If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
564.50    -1.00 (-0.18%)
Bid:
564.50
Ask:
565.50
Spread: 1.00 (0.177%)
Market Cap: £1.53b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Trading Update

27 Nov 2012 07:00

RNS Number : 0473S
Chemring Group PLC
27 November 2012
 



 

 

FOR IMMEDIATE RELEASE 27 November 2012

 

CHEMRING GROUP PLC

 

 Trading Update

 

 

Chemring Group PLC ("Chemring" or "the Group") today provides an update on trading having entered the close period in respect of its preliminary results for the financial year ended 31 October 2012.

 

Trading

 

The Group's performance during 2012 was extremely disappointing. Chemring's operational performance has been weak, and management of investors' expectations over the past year has also been poor. In part, this resulted from a failure to anticipate the likely impact of the changing market dynamics on the Group's businesses, but also reflected failures in performance at several of our businesses.

 

Expectations for the Group's trading performance for the financial year ended 31 October 2012 remain in line with the trading update issued on 1 November 2012. The following further detail is subject to final audit.

 

Trading in the final quarter was impacted by the issues set out in the 1 November 2012 trading statement that principally affected the Countermeasures and Munitions business segments. As a result, turnover for the financial year ended 31 October 2012 is expected to be approximately £740 million (2011: £725 million).

 

The year end order book of approximately £760 million compares to £878.3 million at the prior year end.

 

Financial position

 

There was a significant operating cash inflow in the final quarter that resulted in net debt at the year end of approximately £250 million. (2011: £262.7 million).

 

Market conditions

 

Defence spending in the US, UK and Europe is expected to remain under significant pressure.

 

The US defence market remains vulnerable to ongoing budget uncertainties, particularly around sequestration and the impact of a six month continuing resolution from 1 October 2012. The threat of sequestration continues to have a negative impact on customer behaviour, and there is a lack of clarity about defence expenditure in the medium term. As a result, we are seeing delays in the procurement process whilst customers await greater visibility and certainty as to their future budgets.

 

The UK MoD's review of its procurement process continues to result in delays to the start of new programmes and reduced funding for existing ones whilst, in Europe, ongoing deficit reduction programmes are exerting downward pressure on defence spending, leading to uncertainty in the procurement process and delayed programme implementation.

 

Chemring's non-NATO markets continue to offer opportunities, although order intake remains subject to the granting of export licence approval, which is proving more difficult to achieve in some markets.

 

Outlook

 

The wider market backdrop is likely to remain challenging. Chemring needs to adapt and better equip itself in order to meet these challenges.

 

Mark Papworth joined Chemring as Chief Executive Officer on 5 November 2012, and brings significant experience of delivering performance improvement and implementation of strategic change in the manufacturing, technology and service sectors. He will present his initial views on Chemring and his operational priorities at the Group's preliminary results which are expected to be announced on 24 January 2013.

 

 

- Ends -

 

 

A conference call for analysts and investors will be held at 08.30 GMT today. Dial-in details are as follows:

 

Participant dial in: +44 (0)20 3140 0668 (toll) / 0800 368 1950 (toll free)

PIN: 475152#.

 

A playback facility will be available for 30 days. Dial-in details are 020 3140 0698/0800 368 1890

PIN: 388348#

 

 

For further information:

 

Chemring Group PLC:

 

Rupert Pittman Director of Communications 01489 881 880

& Investor Relations rupertp@chemring.co.uk

 

MHP Communications:

 

Andrew Jaques / John Olsen / James White 0203 128 8100

chemringplc@mhpc.com

 

Cautionary statement: 

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBKADNOBDDCDB
Date   Source Headline
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
15th Dec 20212:00 pmRNSDirector/PDMR Shareholding
14th Dec 20214:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSResults for the year ended 31 October 2021
1st Dec 202110:04 amRNSTotal Voting Rights
2nd Nov 20217:00 amRNSTrading Update and Contract Awards
1st Nov 20213:37 pmRNSTotal Voting Rights
8th Oct 20217:00 amRNSStatement re CFC Finance Company Exemption
1st Oct 20219:34 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSContract Awards
14th Sep 20217:00 amRNSScheduled Trading Update
1st Sep 202110:11 amRNSTotal Voting Rights
2nd Aug 202110:36 amRNSTotal Voting Rights
20th Jul 20212:59 pmRNSDirector/PDMR Shareholding
16th Jul 20219:59 amRNSDirector/PDMR Shareholding
1st Jul 202110:21 amRNSTotal Voting Rights
18th Jun 20211:25 pmRNSBlock listing Interim Review
3rd Jun 20217:00 amRNSAcquisition
3rd Jun 20217:00 amRNSInterim Results
1st Jun 202111:51 amRNSTotal Voting Rights
12th May 20214:18 pmRNSHolding(s) in Company
7th May 20213:59 pmRNSHolding(s) in Company
4th May 202110:38 amRNSTotal Voting Rights
13th Apr 20211:35 pmRNSDirector/PDMR Shareholding
8th Apr 202112:02 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
12th Mar 20217:00 amRNSHolding(s) in Company
5th Mar 20213:05 pmRNSDoc re. Ordinary & Special Resolutions
4th Mar 20211:42 pmRNSResult of AGM
4th Mar 20217:00 amRNSAGM Statement
1st Mar 20213:30 pmRNSTotal Voting Rights
18th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 202112:09 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSHolding(s) in Company
25th Jan 20213:55 pmRNSNotice of AGM
19th Jan 20213:52 pmRNSDirector/PDMR Shareholding
19th Jan 20213:47 pmRNSDirector/PDMR Shareholding
19th Jan 20213:43 pmRNSDirector/PDMR Shareholding
19th Jan 20213:42 pmRNSDirector/PDMR Shareholding
4th Jan 202111:01 amRNSTotal Voting Rights
23rd Dec 202010:07 amRNSHolding(s) in Company
22nd Dec 20201:46 pmRNSCorrection re. Additional Listing
22nd Dec 20201:08 pmRNSAdditional Listing
22nd Dec 20209:39 amRNSHolding(s) in Company
18th Dec 202010:25 amRNSBlock listing Interim Review
17th Dec 20207:00 amRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.